ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0711

Improvement in Excess Mortality in Patients with Rheumatoid Arthritis over the Last Two Decades: A Danish Population-based Matched Cohort Study

Bolette Soussi1, Kirsten Duch1, René Cordtz1, Christian Bork2, Salome Kristensen1, Erik Schmidt2, Jesper Lindhardsen3 and Lene Dreyer1, 1Center of Rheumatic Research Aalborg, Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark, 2Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark, 3Lupus and Vasculitis Clinic, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark

Meeting: ACR Convergence 2022

Keywords: Epidemiology, Mortality, rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: Epidemiology and Public Health Poster I

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: Results from previous studies investigating mortality trends in patients with rheumatoid arthritis (RA) have been inconsistent, most likely due to varying cohort sizes and characteristics. We therefore sought to estimate the temporal trend in 5-year all-cause mortality in a large nationwide unselected cohort of RA patients.

Methods: Danish nationwide population-based matched cohort study. Patients with RA diagnosed between 1996 and the end of 2015 were identified by record linkage using Danish health registers and followed until the end of 2020; thus, allowing 5 full years of follow-up across all calendar groups.

RA was defined as a first-time registration of a M05 and M06 (except M06.1) ICD-10 code and a redeemed prescription of a conventional synthetic disease-modifying anti-rheumatic drug in the following year. Patients with incident RA were matched 1:5 on year of birth and sex with non-RA individuals from the general population by exposure density sampling. Patients and controls were considered at risk from the diagnosis/matching index date to the date of 5 years follow-up, death, emigration, or, for matched controls, to the date of a RA diagnosis, whichever occurred first. Matched controls from the period between 1996 to 2000 were used as reference group.

Pseudo-observations for the cumulative incidence proportion (CIP) were calculated assuming independent censoring. Generalized linear regression with robust variance estimator was used to estimate the risk difference (RD) and relative risk (RR) for age-adjusted all-cause mortality for RA patients compared with controls. Restricted cubic splines with 4 knots were used to adjust for age with median age as reference.

Results: In total, 29 163 patients with incident RA and 145 792 matched controls were identified. The 5-year CIP of death for a 60-year-old RA patient decreased from 8.2 % in 1996 to 2000 to 3.1 % in 2011 to 2015, while the decrease seen in matched controls was from 4.9 % to 2.1 % (Table 1). The age-adjusted all-cause CIP of death was higher for patients with RA compared to matched controls in all calendar periods, with RDs ranging from 3.4 % in 1996 to 2000 to -1.7 % in 2011 to 2015 when compared to the reference group. In the same period the RD for matched controls decreased with -2.8 %. Similar, the RR decreased from 1.3 in 1996 to 2000 to 0.9 in 2011 to 2015 for patients with RA, and to 0.8 for matched controls in 2011 to 2015 when compared to the reference group. Sex-specific analyses revealed similar temporal and RD patterns in men and women.

Conclusion: Five-year all-cause mortality risk decreased over time for both patients with RA and matched controls indicating temporal improvements in mortality related factors in both groups. In line with the established excess mortality in RA patients, a higher percentage of patients with RA died compared to matched controls across all calendar periods. The differences between the groups attenuated with time. This probably reflects the improved treatment regimens for RA, increased focus on treating comorbidities and lifestyle factors in RA patients.

Supporting image 1


Disclosures: B. Soussi, Novo Nordisk; K. Duch, None; R. Cordtz, None; C. Bork, None; S. Kristensen, None; E. Schmidt, None; J. Lindhardsen, None; L. Dreyer, Bristol-Myers Squibb(BMS).

To cite this abstract in AMA style:

Soussi B, Duch K, Cordtz R, Bork C, Kristensen S, Schmidt E, Lindhardsen J, Dreyer L. Improvement in Excess Mortality in Patients with Rheumatoid Arthritis over the Last Two Decades: A Danish Population-based Matched Cohort Study [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/improvement-in-excess-mortality-in-patients-with-rheumatoid-arthritis-over-the-last-two-decades-a-danish-population-based-matched-cohort-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/improvement-in-excess-mortality-in-patients-with-rheumatoid-arthritis-over-the-last-two-decades-a-danish-population-based-matched-cohort-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology